AVITA Medical Expects To Achieve Previously Given Guidance Of Cashflow Break Even And GAAP Profitability No Later Than The End Of Q3 Of 2025
Portfolio Pulse from Benzinga Newsdesk
AVITA Medical expects to achieve cashflow break-even and GAAP profitability by the end of Q3 2025. The company projects commercial revenue for Q3 2024 to be between $19.0 to $20.0 million, a 40% to 48% increase over Q3 2023. Full-year 2024 revenue is expected to be between $68.0 to $70.0 million, a 37% to 41% increase over 2023.
August 08, 2024 | 9:29 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AVITA Medical (RCEL) expects to achieve cashflow break-even and GAAP profitability by the end of Q3 2025. The company projects significant revenue growth for Q3 2024 and full-year 2024.
The positive revenue projections and the goal of achieving profitability by Q3 2025 are likely to boost investor confidence in AVITA Medical (RCEL). The significant growth in revenue for both Q3 2024 and full-year 2024 indicates strong business performance, which is expected to positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100